Napabucasin |
DP1; DP2A; BB-608; GB-201; BBI-608; BBI-608-DP1; BBI-608-DP2A; Z1HHM49K7O (UNII code) |
Phase 3 Clinical |
1globe Biomedical Co Ltd, Pharmaceutics International Inc, Boston Biomedical Inc |
Hematologic Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Neoplasms; Glioblastoma; Mesothelioma; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms |
Details
|
Nanocurcumin (Tehran University of Medical Sciences) |
|
Phase 2 Clinical |
Tehran University Of Medical Sciences |
Neoplasms; Periapical Diseases |
Details
|
OPB-111077 |
OPB-111077 |
Phase 2 Clinical |
Otsuka Pharmaceutical Co Ltd |
Lymphoma, B-Cell; Solid tumours; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Nasopharyngeal Carcinoma; Leukemia, Myeloid, Acute; Carcinoma, Hepatocellular |
Details
|
Danvatirsen |
AZD-9150; STAT-3Rx; ISIS-345794; ISIS-481464; ISIS-STAT3Rx; IONIS-STAT3Rx; ISIS-STAT3-2.5Rx; IONIS-STAT3-2.5Rx |
Phase 2 Clinical |
Ionis Pharmaceuticals Inc |
Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Mismatch Repair Deficient Cancer; Lymphoma, Large B-Cell, Diffuse; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Ascites; Colorectal Neoplasms; Lymphoma, Non-Hodgkin; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms |
Details
|
HL-237 |
HL-237 |
Phase 2 Clinical |
Hanlim Pharmaceutical Co Ltd |
Arthritis, Rheumatoid |
Details
|
M-1001 |
M-1001; MEDICA-M1001 |
Phase 2 Clinical |
Syndromex |
Dyslipidemias |
Details
|
NT-219 |
NT-219; NT219 |
Phase 2 Clinical |
TyrNovo Ltd |
Solid tumours; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Neoplasm Metastasis |
Details
|
Dimethylaminomicheliolide Fumarate |
ACT-001 |
Phase 2 Clinical |
Tianjin Accendatech Technology Co Ltd |
Glioblastoma; Small Cell Lung Carcinoma; Ganglioglioma; Central Nervous System Neoplasms; Optic Neuritis; Neuromyelitis Optica; Breast Neoplasms; Glioma; Brain metastases; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma |
Details
|
C-188-9 |
C188-9; C-188-9; TTI-101 |
Phase 2 Clinical |
Baylor College Of Medicine |
Liver Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Neoplasms; Idiopathic Pulmonary Fibrosis; Pancreatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung |
Details
|
WP-1066 |
WP-1066 |
Phase 2 Clinical |
The University Of Texas MD Anderson Cancer Center |
Medulloblastoma; Glioblastoma; Neoplasms; Brain Neoplasms; Brain metastases; Glioma; Melanoma |
Details
|
YY-201 |
YY-201; YY201 |
Phase 1 Clinical |
Shanghai Yuyao Biotechnology Co Ltd |
Hematologic Neoplasms; Solid tumours; Prostatic Hyperplasia |
Details
|
GLG-302 |
GLG-302; GLG-805; S31-201; NSC-74859 |
Phase 1 Clinical |
H Lee Moffitt Cancer Center & Research Institute |
Breast Neoplasms |
Details
|
MOL-4239 |
MOL-4239; WP-1220 |
Phase 1 Clinical |
The University Of Texas MD Anderson Cancer Center |
Psoriasis; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides |
Details
|
Amcasertib/Napabucasin |
|
Phase 1 Clinical |
Boston Biomedical Inc |
Neoplasms |
Details
|
KT-333 |
KT-333; I-003 |
Phase 1 Clinical |
Kymera Therapeutics Inc |
Lymphoma, T-Cell, Peripheral; Solid tumours; Leukemia, Lymphoid; Neoplasms; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Leukemia, Large Granular Lymphocytic |
Details
|
VVD-130850 |
VVD-130850; BAY-3630914 |
Phase 1 Clinical |
Vividion Therapeutics Inc |
Solid tumours |
Details
|
[14C]ACT-001 |
[14C]ACT001 |
Phase 1 Clinical |
Tianjin Xinyi Shangde Biomedical Technology Co Ltd |
Solid tumours |
Details
|
DCR-STAT3 |
DCR-STAT3 |
Phase 1 Clinical |
Dicerna Pharmaceuticals Inc |
Solid tumours; Neoplasms |
Details
|
OPB-171775 |
OPB-171775 |
Phase 1 Clinical |
Otsuka Pharmaceutical Co Ltd |
Metabolic Dysfunction-Associated Steatotic Liver Disease |
Details
|
Napabucasin |
DP1; DP2A; BB-608; GB-201; BBI-608; BBI-608-DP1; BBI-608-DP2A; Z1HHM49K7O (UNII code) |
Phase 3 Clinical |
1globe Biomedical Co Ltd, Pharmaceutics International Inc, Boston Biomedical Inc |
Hematologic Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Neoplasms; Glioblastoma; Mesothelioma; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms |
Details
|
Nanocurcumin (Tehran University of Medical Sciences) |
|
Phase 2 Clinical |
Tehran University Of Medical Sciences |
Neoplasms; Periapical Diseases |
Details
|
OPB-111077 |
OPB-111077 |
Phase 2 Clinical |
Otsuka Pharmaceutical Co Ltd |
Lymphoma, B-Cell; Solid tumours; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Nasopharyngeal Carcinoma; Leukemia, Myeloid, Acute; Carcinoma, Hepatocellular |
Details
|
Danvatirsen |
AZD-9150; STAT-3Rx; ISIS-345794; ISIS-481464; ISIS-STAT3Rx; IONIS-STAT3Rx; ISIS-STAT3-2.5Rx; IONIS-STAT3-2.5Rx |
Phase 2 Clinical |
Ionis Pharmaceuticals Inc |
Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Mismatch Repair Deficient Cancer; Lymphoma, Large B-Cell, Diffuse; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Ascites; Colorectal Neoplasms; Lymphoma, Non-Hodgkin; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms |
Details
|
HL-237 |
HL-237 |
Phase 2 Clinical |
Hanlim Pharmaceutical Co Ltd |
Arthritis, Rheumatoid |
Details
|
M-1001 |
M-1001; MEDICA-M1001 |
Phase 2 Clinical |
Syndromex |
Dyslipidemias |
Details
|
NT-219 |
NT-219; NT219 |
Phase 2 Clinical |
TyrNovo Ltd |
Solid tumours; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Neoplasm Metastasis |
Details
|
Dimethylaminomicheliolide Fumarate |
ACT-001 |
Phase 2 Clinical |
Tianjin Accendatech Technology Co Ltd |
Glioblastoma; Small Cell Lung Carcinoma; Ganglioglioma; Central Nervous System Neoplasms; Optic Neuritis; Neuromyelitis Optica; Breast Neoplasms; Glioma; Brain metastases; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma |
Details
|
C-188-9 |
C188-9; C-188-9; TTI-101 |
Phase 2 Clinical |
Baylor College Of Medicine |
Liver Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Neoplasms; Idiopathic Pulmonary Fibrosis; Pancreatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung |
Details
|
WP-1066 |
WP-1066 |
Phase 2 Clinical |
The University Of Texas MD Anderson Cancer Center |
Medulloblastoma; Glioblastoma; Neoplasms; Brain Neoplasms; Brain metastases; Glioma; Melanoma |
Details
|
YY-201 |
YY-201; YY201 |
Phase 1 Clinical |
Shanghai Yuyao Biotechnology Co Ltd |
Hematologic Neoplasms; Solid tumours; Prostatic Hyperplasia |
Details
|
GLG-302 |
GLG-302; GLG-805; S31-201; NSC-74859 |
Phase 1 Clinical |
H Lee Moffitt Cancer Center & Research Institute |
Breast Neoplasms |
Details
|
MOL-4239 |
MOL-4239; WP-1220 |
Phase 1 Clinical |
The University Of Texas MD Anderson Cancer Center |
Psoriasis; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides |
Details
|
Amcasertib/Napabucasin |
|
Phase 1 Clinical |
Boston Biomedical Inc |
Neoplasms |
Details
|
KT-333 |
KT-333; I-003 |
Phase 1 Clinical |
Kymera Therapeutics Inc |
Lymphoma, T-Cell, Peripheral; Solid tumours; Leukemia, Lymphoid; Neoplasms; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Leukemia, Large Granular Lymphocytic |
Details
|
VVD-130850 |
VVD-130850; BAY-3630914 |
Phase 1 Clinical |
Vividion Therapeutics Inc |
Solid tumours |
Details
|
[14C]ACT-001 |
[14C]ACT001 |
Phase 1 Clinical |
Tianjin Xinyi Shangde Biomedical Technology Co Ltd |
Solid tumours |
Details
|
DCR-STAT3 |
DCR-STAT3 |
Phase 1 Clinical |
Dicerna Pharmaceuticals Inc |
Solid tumours; Neoplasms |
Details
|
OPB-171775 |
OPB-171775 |
Phase 1 Clinical |
Otsuka Pharmaceutical Co Ltd |
Metabolic Dysfunction-Associated Steatotic Liver Disease |
Details
|